Patents by Inventor Matthew Stirling

Matthew Stirling has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Process for the synthesis of E1 activating enzyme inhibitors
    Patent number: 10745404
    Abstract: The present invention provides processes and synthetic intermediate (Ia) for the synthesis of 4-substituted ((1S, 2S, 4R)-2-hydroxy-4-{7H-pyrrolo[2,3-d]pyrimidin-7-yl}cyclopentyl)methyl sulfamates. These sulfamate compounds are E1 activating enzyme inhibitors, and are useful for the treatment of disorders of cell proliferation, particularly cancer, and other disorders associated with E1 activity.
    Type: Grant
    Filed: September 22, 2017
    Date of Patent: August 18, 2020
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Ian Armitage, Eric L. Elliott, Marianne Langston, Steven P. Langston, Quentin J. McCubbin, Hiro Mizutani, Matthew Stirling, Lei Zhu
  • INHIBITORS OF NEDD8-ACTIVATING ENZYME
    Publication number: 20180290983
    Abstract: Disclosed are chemical entities which are inhibitors of Nedd8-activating enzyme (NAE), namely, the compound {(1S,2S,4R)-4-[(6-{[(1R,2S)-5-chloro-2-methoxy-2,3-dihydro-1H-inden-1-yl]amino}pyrimidin-4-yl)oxy]-2-hydroxycyclopentyl}methyl sulfamate and pharmaceutically acceptable salts thereof; solid state forms thereof; and prodrugs thereof. Also disclosed are methods of using the chemical entities to treat disorders such as cancer.
    Type: Application
    Filed: November 9, 2017
    Publication date: October 11, 2018
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Ashley Sue MCCARRON, Todd B. SELLS, Matthew STIRLING, Stephen G. STROUD
  • PROCESS FOR THE SYNTHESIS OF E1 ACTIVATING ENZYME INHIBITORS
    Publication number: 20180079755
    Abstract: The present invention provides processes and synthetic intermediates for the synthesis of 4-substituted ((4S, 2S, 4R)-2-hydroxy-4-{7H-pyrrolo[2,3-d]pyrimidin-7-yl}cyclopentyl)methyl sulfamates, which are E1 activating enzyme inhibitors, and are useful for the treatment of disorders of cell proliferation, particularly cancer, and other disorders associated with E1 activity.
    Type: Application
    Filed: September 22, 2017
    Publication date: March 22, 2018
    Inventors: Ian Armitage, Eric L. Elliott, Marianne Langston, Steven P. Langston, Quentin J. McCubbin, Hiro Mizutani, Matthew Stirling, Lei Zhu
  • Inhibitors of NEDD8-activating enzyme
    Patent number: 9850214
    Abstract: Disclosed are chemical entities which are inhibitors of Nedd8-activating enzyme (NAE), namely, the compound {(1S,2S,4R)-4-[(6-{[(1R,2S)-5-chloro-2-methoxy-2,3-dihydro-1H-inden-1-yl]amino}pyrimidin-4-yl)oxy]-2-hydroxycyclopentyl}methyl sulfamate and pharmaceutically acceptable salts thereof; solid state forms thereof; and prodrugs thereof. Also disclosed are methods of using the chemical entities to treat disorders such as cancer.
    Type: Grant
    Filed: July 8, 2014
    Date of Patent: December 26, 2017
    Assignee: MILLENNIUM PHARMACEUTICALS, INC.
    Inventors: Ashley Sue McCarron, Todd B. Sells, Matthew Stirling, Stephen G. Stroud
  • Sulfamoylating reagents
    Patent number: 9802938
    Abstract: The present invention provides sulfamoylating reagents of formula RuN?—S(O)2X+, wherein X is a cyclic tertiary amine or a nitrogen-containing heteroaryl and Ru is an amine protecting group or hydrogen.
    Type: Grant
    Filed: November 25, 2014
    Date of Patent: October 31, 2017
    Assignee: MILLENNIUM PHARMACEUTICALS, INC.
    Inventors: Ian Armitage, Eric L. Elliott, Marianne Langston, Steven P. Langston, Quentin J. McCubbin, Hiro Mizutani, Matthew Stirling, Lei Zhu
  • PROCESS FOR THE SYNTHESIS OF E1 ACTIVATING ENZYME INHIBITORS
    Publication number: 20150353555
    Abstract: The present invention provides processes and synthetic intermediates for the synthesis of 4-substituted ((1S,2S,4R)-2-hydroxy-4-{7H-pyrrolo[2,3-d]pyrimidin-7-yl}cyclopentyl)methyl sulfamates, which are E1 activating enzyme inhibitors, and are useful for the treatment of disorders of cell proliferation, particularly cancer, and other disorders associated with E1 activity.
    Type: Application
    Filed: November 25, 2014
    Publication date: December 10, 2015
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Ian Armitage, Eric L. Elliott, Marianne Langston, Steven P. Langston, Quentin J. McCubbin, Hiro Mizutani, Matthew Stirling, Lei Zhu
  • PROCESS FOR THE SYNTHESIS OF E1 ACTIVATING ENZYME INHIBITORS
    Publication number: 20150080573
    Abstract: The present invention provides processes and synthetic intermediates for the synthesis of 4-substituted ((1S,2S,4R)-2-hydroxy-4-{7H-pyrrolo[2,3-d]pyrimidin-7-yl}cyclopentyl)methyl sulfamates, which are E1 activating enzyme inhibitors, and are useful for the treatment of disorders of cell proliferation, particularly cancer, and other disorders associated with E1 activity.
    Type: Application
    Filed: November 25, 2014
    Publication date: March 19, 2015
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Ian Armitage, Eric L. Elliott, Marianne Langston, Steven P. Langston, Quentin J. McCubbin, Hiro Mizutani, Matthew Stirling, Lei Zhu
  • Process for the synthesis of E1 activating enzyme inhibitors
    Patent number: 8933225
    Abstract: Disclosed are processes and synthetic intermediates for the synthesis of compounds of formula (V) wherein the variables have the definitions contained herein. Such compounds are E1 activating enzyme inhibitors, and are useful for the treatment of disorders of cell proliferation, particularly cancer, and other disorders associated with E1 activity.
    Type: Grant
    Filed: August 1, 2008
    Date of Patent: January 13, 2015
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Ian Armitage, Eric L. Elliott, Marianne Langston, Steven P. Langston, Quentin J. McCubbin, Hirotake Mizutani, Matthew Stirling, Lei Zhu
  • INHIBITORS OF NEDD8-ACTIVATING ENZYME
    Publication number: 20150011572
    Abstract: Disclosed are chemical entities which are inhibitors of Nedd8-activating enzyme (NAE), namely, the compound {(1S,2S,4R)-4-[(6-{[(1R,2S)-5-chloro-2-methoxy-2,3-dihydro-1H-inden-1-yl]amino}pyrimidin-4-yl)oxy]-2-hydroxycyclopentyl}methyl sulfamate and pharmaceutically acceptable salts thereof; solid state forms thereof; and prodrugs thereof. Also disclosed are methods of using the chemical entities to treat disorders such as cancer.
    Type: Application
    Filed: July 8, 2014
    Publication date: January 8, 2015
    Applicant: MILLENNIUM PHARMACEUTICALS, INC.
    Inventors: Ashley Sue McCarron, Todd B. Sells, Matthew Stirling, Stephen G. Stroud
  • Inhibitors of NEDD8-activating enzyme
    Patent number: 8809356
    Abstract: Disclosed are chemical entities which are inhibitors of Nedd8-activating enzyme (NAE), namely, the compound {(1S,2S,4R)-4-[(6-{[(1R,2S)-5-chloro-2-methoxy-2,3-dihydro-1H-inden-1-yl]amino}pyrimidin-4-yl)oxy]-2-hydroxycyclopentyl}methyl sulfamate and pharmaceutically acceptable salts thereof; solid state forms thereof; and prodrugs thereof. Also disclosed are methods of using the chemical entities to treat disorders such as cancer.
    Type: Grant
    Filed: August 23, 2012
    Date of Patent: August 19, 2014
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Ashley Sue McCarron, Todd B. Sells, Matthew Stirling, Stephen G. Stroud
  • INHIBITORS OF NEDD8-ACTIVATING ENZYME
    Publication number: 20130150388
    Abstract: Disclosed are chemical entities which are inhibitors of Nedd8-activating enzyme (NAE), namely, the compound {(1S,2S,4R)-4-[(6-{[(1R,2S)-5-chloro-2-methoxy-2,3-dihydro-1H-inden-1-yl]amino}pyrimidin-4-yl)oxy]-2-hydroxycyclopentyl}methyl sulfamate and pharmaceutically acceptable salts thereof; solid state forms thereof; and prodrugs thereof. Also disclosed are methods of using the chemical entities to treat disorders such as cancer.
    Type: Application
    Filed: August 23, 2012
    Publication date: June 13, 2013
    Applicant: MILLENNIUM PHARMACEUTICALS, INC.
    Inventors: Ashley Sue McCarron, Todd B. Sells, Matthew Stirling, Stephen G. Stroud
  • LACTAM COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS
    Publication number: 20120178739
    Abstract: The present invention provides novel compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.
    Type: Application
    Filed: March 14, 2012
    Publication date: July 12, 2012
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Christopher Blackburn, Christopher F. Claiborne, Courtney A. Cullis, Natalie A. Dales, Michael Patane, Matthew Stirling, Omar Stradella, Gabriel S. Weatherhead
  • Lactam compounds useful as protein kinase inhibitors
    Patent number: 7935694
    Abstract: The present invention provides novel compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.
    Type: Grant
    Filed: September 4, 2008
    Date of Patent: May 3, 2011
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Christopher Blackburn, Christopher F. Claiborne, Courtney A. Cullis, Natalie A. Dales, Michael Patane, Matthew Stirling, Omar Stradella, Gabriel S. Weatherhead
  • LACTAM COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS
    Publication number: 20110039820
    Abstract: The present invention provides novel compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.
    Type: Application
    Filed: October 13, 2010
    Publication date: February 17, 2011
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Christopher Blackburn, Christopher F. Claiborne, Courtney A. Cullis, Natalie A. Dales, Michael Patane, Matthew Stirling, Omar Stradella, Gabriel S. Weatherhead
  • Lactam compounds useful as protein kinase inhibitors
    Publication number: 20090105213
    Abstract: The present invention provides novel compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.
    Type: Application
    Filed: September 4, 2008
    Publication date: April 23, 2009
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Christopher Blackburn, Christopher F. Claiborne, Courtney A. Cullis, Natalie A. Dales, Michael Patane, Matthew Stirling, Omar Stradella, Gabriel S. Weatherhead
  • Process for the synthesis of E1 activating enzyme inhibitors
    Publication number: 20090036678
    Abstract: The present invention provides processes and synthetic intermediates for the synthesis of 4-substituted ((1S,2S,4R)-2-hydroxy-4-{7H-pyrrolo[2,3-d]pyrimidin-7-yl}cyclopentyl)methyl sulfamates, which are E1 activating enzyme inhibitors, and are useful for the treatment of disorders of cell proliferation, particularly cancer, and other disorders associated with E1 activity.
    Type: Application
    Filed: August 1, 2008
    Publication date: February 5, 2009
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Ian Armitage, Eric L. Elliott, Marianne Langston, Steven P. Langston, Quentin J. McCubbin, Hirotake Mizutani, Matthew Stirling, Lei Zhu
  • Lactam compounds useful as protein kinase inhibitors
    Patent number: 7459448
    Abstract: The present invention provides novel compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.
    Type: Grant
    Filed: October 3, 2005
    Date of Patent: December 2, 2008
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Christopher Blackburn, Christopher F. Claiborne, Courtney A. Cullis, Natalie A. Dales, Michael Patane, Matthew Stirling, Omar Stradella, Gabriel S. Weatherhead
  • Lactam compounds useful as protein kinase inhibitors
    Publication number: 20060100194
    Abstract: The present invention provides novel compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.
    Type: Application
    Filed: October 3, 2005
    Publication date: May 11, 2006
    Inventors: Christopher Blackburn, Christopher Claiborne, Courtney Cullis, Natalie Dales, Michael Patane, Matthew Stirling, Omar Stradella, Gabriel Weatherhead
  • Calixarenes
    Patent number: 6358431
    Abstract: A method of imparting a water repellent surface to a hydrophilic substrate which comprises contacting the substrate with a solution or dispersion of a suitable calixarene in a liquid medium.
    Type: Grant
    Filed: February 24, 1999
    Date of Patent: March 19, 2002
    Assignee: The University of Sheffield
    Inventors: Charles James Matthew Stirling, Frank Davis